Compare · GILD vs IMVT
GILD vs IMVT
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Immunovant Inc. (IMVT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and IMVT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $163.51B, about 20.0x IMVT ($8.19B).
- Over the past year, GILD is up 19.9% and IMVT is up 124.0% - IMVT leads by 104.1 points.
- IMVT has been more active in the news (12 items in the past 4 weeks vs 5 for GILD).
- Both have 25 recent analyst ratings on file.
- Company
- Gilead Sciences Inc.
- Immunovant Inc.
- Price
- $131.66+1.28%
- $39.88+2.94%
- Market cap
- $163.51B
- $8.19B
- 1M return
- +4.82%
- +18.71%
- 1Y return
- +19.88%
- +124.01%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2019
- News (4w)
- 5
- 12
- Recent ratings
- 25
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Immunovant Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Latest GILD
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
Latest IMVT
- Chief Operating Officer Gloria Melanie sold $80,532 worth of shares (2,036 units at $39.55), decreasing direct ownership by 0.91% to 222,357 units (SEC Form 4) to satisfy withholding tax
- Chief Legal Officer Van Tuyl Christopher sold $47,702 worth of shares (1,206 units at $39.55), decreasing direct ownership by 0.67% to 179,391 units (SEC Form 4) to satisfy withholding tax
- Chief Technology Officer Stout Jay S sold $137,925 worth of shares (3,487 units at $39.55), decreasing direct ownership by 2% to 208,198 units (SEC Form 4) (tax withholding)
- Chief Executive Officer Venker Eric sold $118,980 worth of shares (3,092 units at $38.48), exercised 92,188 shares at a strike of $14.46 and returned $3,304,030 worth of shares to the company (86,629 units at $38.14), increasing direct ownership by 0.98% to 254,280 units (SEC Form 4) (withholding obligation)
- Chief Operating Officer Gloria Melanie sold $678,604 worth of shares (17,714 units at $38.31), decreasing direct ownership by 7% to 224,393 units (SEC Form 4)
- Chief Technology Officer Stout Jay S sold $1,532,309 worth of shares (40,000 units at $38.31), decreasing direct ownership by 16% to 211,685 units (SEC Form 4)
- Chief Legal Officer Van Tuyl Christopher exercised 17,824 shares at a strike of $15.20 and sold $682,887 worth of shares (17,824 units at $38.31) (SEC Form 4)
- Chief Financial Officer Girao Tiago exercised 10,000 shares at a strike of $15.90 and sold $384,600 worth of shares (10,000 units at $38.46) (SEC Form 4)
- Director Pande Atul exercised 1,500 shares at a strike of $8.43 and sold $57,015 worth of shares (1,500 units at $38.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Immunovant Inc.